Short Summary
The PTAB denied institution of an IPR challenging Tesla's patent 7,925,426 against iQar Inc., finding that the petitioner failed to demonstrate a reasonable likelihood of prevailing on any challenged claim.
Detailed Summary
Tesla, Inc. petitioned for an Inter Partes Review (IPR) against iQar Inc.'s patent 7,925,426 B2, challenging claims 1-4 based on obviousness under 35 U.S.C. § 103. The Board denied institution because Tesla failed to meet the burden of showing a reasonable likelihood of success. Specifically, regarding Claim 1, the Board found that while prior art references (Neiss and Ran) taught components like optimized speed and probable speed, the Petition did not adequately explain how these elements combine to satisfy the claim limitation requiring 'determining an efficient speed based on said optimized speed and said probable speed.'
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in TESLA, INC. vs iQar Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Amazon.com, Inc. et al.vsNokia Technologies Oy
Amazon and Nokia reached a settlement, leading to a joint motion that terminated the IPRs covering Nokia’s patent 8,918,741. The Board granted the motion and treated the settlement documents as confidential.
Kingston Technology Company, Inc., Kingston Technology Corporation, and Kingston Digital, Inc. et al.vsVervain, LLC
The PTAB denied Phison Electronics' post‑grant review petition against Vervain’s NAND‑flash storage patent, finding the claims patent‑eligible and adequately supported. No claims were found unpatentable.
Cisco Systems, Inc.vs--
Cisco Systems has filed a petition for inter partes review of U.S. Patent 8,780,887, asserting that its ten claims are obvious over the Pankratov prior‑art reference. The petition seeks institution of the IPR and cancellation of the challenged claims.
Mercedes-Benz Group AG et al.vsPhelan Group, LLC
Mercedes‑Benz and The Phelan Group jointly filed a motion asking the PTAB to keep their settlement agreement confidential while seeking to terminate the IPR over patent 9,045,101.
Imperative Care, Inc.vsInari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success. All challenged claims (1‑7, 9‑10, 15‑18, 20‑24) are now under review.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.